Artisan Partners Limited Partnership Has $30.17 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Artisan Partners Limited Partnership raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 36.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 337,234 shares of the medical equipment provider's stock after purchasing an additional 89,468 shares during the quarter. Artisan Partners Limited Partnership owned about 0.49% of Lantheus worth $30,169,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D increased its holdings in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC lifted its holdings in shares of Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after buying an additional 129 shares during the last quarter. Avantax Advisory Services Inc. grew its position in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after purchasing an additional 132 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. Finally, Aurora Investment Counsel raised its stake in shares of Lantheus by 0.8% in the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock worth $6,110,806. Corporate insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Finally, Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.46 during trading on Wednesday, hitting $97.48. The stock had a trading volume of 157,554 shares, compared to its average volume of 939,056. The company has a market capitalization of $6.68 billion, a PE ratio of 16.22 and a beta of 0.38. Lantheus Holdings, Inc. has a 12 month low of $58.16 and a 12 month high of $126.89. The company's 50-day moving average price is $93.41 and its two-hundred day moving average price is $96.28.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.